About 22 results found for searched term "DM4" (0.064 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M3344 | Nefiracetam | GABA Receptor |
| DZL 221; DM9384 | ||
| Nefiracetam is a GABAergic, cholinergic, and monoaminergic neuronal systems enhancer for Ro 5-4864-induced convulsions. | ||
| M5580 | Dimethyl Fumarate | NF-κB |
| DMF; LAS41008 | ||
| Dimethyl Fumarate (DMF) is an orally active Monomethyl fumarate (MMF) precursor compound that is also an Nrf2 pathway activator and inhibits NF-κB. In addition, Dimethyl Fumarate also inhibits GAPDH and can be used in studies related to multiple sclerosis (MS) and psoriasis. | ||
| M6683 | DMH4 | Others |
| DMH4 is a selective VEGFR-2 inhibitor. | ||
| M6684 | DMP 543 | Others |
| DMP 543 is a potent, orally active ACh release enhancer. | ||
| M9541 | DM4 | Microtubule |
| Maytansinoid DM4 | ||
| DM4, a chemical derivative of maytansine, is a potent and selective cytotoxic agent that inhibit cell division. | ||
| M9956 | Darolutamide | Androgen Receptor |
| ODM-201; BAY-1841788 | ||
| Darolutamide (ODM-201) is a new-generation, potent and selective androgen receptor (AR) inhibitor. | ||
| M13834 | KDM4D-IN-1 | Histone demethylase |
| KDM4D-IN-1 is a new histone lysine demethylase 4D (KDM4D) inhibitor with an IC50 value of 0.41±0.03 μM. | ||
| M13837 | NCGC00244536 | Histone demethylase |
| KDM4B Inhibitor B3 | ||
| NCGC00244536 is a potent KDM4B inhibitor with an IC50 of 10 nM. | ||
| M14172 | Trametinib (DMSO solvate) | MEK |
| GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate) | ||
| Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. | ||
| M20713 | DMX-5084 | MAPKAPK2/MAP3K/MAP4K |
| DMX-5804 is a potent, orally active and selective inhibitor of Mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K4) with IC50 of 3 nM for human MAP4K4. DMX-5804 is more potent on human MAP4K4 with pIC50 of 8.55 than MINK1/MAP4K6 and TNIK/MAP4K7 with pIC50 of 8.18 and 7.96, respectively. | ||
| M24661 | Sofituzumab vedotin | Drug-Linker Conjugates for ADC |
| DMUC5754A | ||
| Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer. | ||
| M25054 | Tusamitamab ravtansine | Drug-Linker Conjugates for ADC |
| SAR-408701; HuMAb2-3-SPDB-DM4 | ||
| Tusamitamab ravtansine (SAR-408701) is a DM4 anti-CEACAM5 antibody-drug conjugate (ADC). Tusamitamab ravtansine is composed of a humanized monoclonal antibody that binds carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5) and a cytotoxic maytansinoid that selectively targets CEACAM5-expressing tumor cells. | ||
| M25258 | Cantuzumab ravtansine | Drug-Linker Conjugates for ADC |
| IMGN242; huC242-DM4 | ||
| Cantuzumab ravtansine (IMGN242; huC242-DM4), an ADC, is a humanized monoclonal antibody huC242 covalently linked via a disulfide bond to DM4. Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts. | ||
| M28111 | Lys-Nε-SPDB-DM4 | Drug-Linker Conjugates for ADC |
| Lys-Nε-SPDB-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Lys-Nε-SPDB to make antibody agent conjugate (ADC). | ||
| M28498 | Sulfo-PDBA-DM4 | Drug-Linker Conjugates for ADC |
| Sulfo-PDBA-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Sulfo-PDBA to make antibody agent conjugate (ADC). Sulfo-PDBA is a gluthatione cleavable linker. | ||
| M28643 | KDM5-C49 | Histone demethylase |
| KDOAM-20 | ||
| KDM5-C49 (KDOAM-20) is a potent and selective inhibitor of KDM5 demethylases, with IC50s of 40 nM, 160 nM, and 100 nM for KDM5A, KDM5B, and KDM5C enzymes, respectively. KDM5-C49 can be used for the research of cancer. | ||
| M28761 | ODM-204 | Androgen Receptor |
| ODM-204 is novel nonsteroidal dual inhibitor of both androgen receptor and CYP17A1 enzyme, with IC50s of 80 nM and 22 nM, respectively. | ||
| M30126 | Alvespimycin | HSP |
| 17-DMAG; NSC 707545 | ||
| Alvespimycin (17-DMAG) is a potent inhibitor of Hsp90, binding to Hsp90 with an EC50 of 62 ± 29 nM. | ||
| M30500 | RO8191 | Interferon-α/β/γ |
| CDM-3008; RO4948191 | ||
| RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC50 of 200 nM for HCV replicon. RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity. | ||
| M31015 | KDM5-C49 hydrochloride | Histone demethylase |
| KDOAM-20 hydrochloride | ||
| KDM5-C49 (KDOAM-20) hydrochloride is a potent and selective inhibitor of KDM5 demethylases, with IC50s of 40 nM, 160 nM, and 100 nM for KDM5A, KDM5B, and KDM5C enzymes, respectively. KDM5-C49 hydrochloride can be used for the research of cancer. | ||
| M41097 | BDM91514 | Antibiotic |
| BDM91514 improves antibiotic potency through AcrB inhibition. | ||
| M42882 | KDM5B-IN-4 | Others |
| KDM5B-IN-4 is a lysine demethylase 5B (KDM5B) inhibitor with an IC50 of 0.025 μM KDM5B-IN-4 increases substrate H3K4me1/2/3 level by inhibiting KDM5B in PC-3 cells. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
